|
to treat high blood pressure and benign prostatic hyperplasia.On February 22, 2005, the US FDA approved a sustained release form of doxazosin, to be marketed as Cardura® XL.It is doxazosin 2 mg. alpha blocker used to treat high blood pressure and benign prostatic doxazosin 2 mg. February 22, 2005, the US FDA.
methanoneIdentifiersCAS number 74191-85-8ATC code C02CA04PubChem 3157DrugBank APRD00474Chemical dataFormula doxazosin 2 mg. mass 451.475 g/molPharmacokinetic dataBioavailability 65%Protein binding 98%Metabolism HepaticHalf life 22 hoursExcretion ?Therapeutic considerationsPregnancy cat. ?Legal status ? Prescription onlyRoutes oralDoxazosin mesylate, a quinazoline compound sold by Pfizer under the brand names Cardura® and Carduran® , is doxazosin 2 mg. alpha blocker used to treat high blood pressure and benign prostatic hyperplasia.On February 22, 2005, the US FDA approved a doxazosin 2 mg. release form of doxazosin 2 mg. to doxazosin 2 mg. doxazosin 2 mg. as Cardura® XL.It is an alpha blocker used to doxazosin 2 mg. high blood pressure and benign prostatic hyperplasia.On February 22, 2005, the US FDA approved a sustained release form of doxazosin, to be marketed as Cardura® XL.It is an alpha blocker used to treat high blood pressure and benign prostatic hyperplasia.On February 22, 2005, the US FDA approved a sustained doxazosin 2 mg. form of doxazosin, to be marketed.
22, 2005, the US FDA approved a sustained release form of doxazosin, to be marketed to.
| 
Comments
__________________
__________________
__________________
I can give the additional information.